Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Nantahala Capital Management LLC

Nantahala Capital Management LLC raised its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 23.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 560,532 shares of the company’s stock after acquiring an additional 107,300 shares during the period. Nantahala Capital Management LLC owned approximately 0.66% of Syndax Pharmaceuticals worth $7,410,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. R Squared Ltd acquired a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth $26,000. Virtus ETF Advisers LLC increased its holdings in shares of Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after purchasing an additional 827 shares in the last quarter. Cape Investment Advisory Inc. increased its holdings in shares of Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock valued at $85,000 after purchasing an additional 3,927 shares in the last quarter. KBC Group NV increased its holdings in shares of Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock valued at $92,000 after purchasing an additional 3,559 shares in the last quarter. Finally, Optimize Financial Inc purchased a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at about $152,000.

Insider Transactions at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares of the company’s stock, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,683 shares of company stock worth $336,087 in the last ninety days. Insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SNDX. HC Wainwright reiterated a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Scotiabank dropped their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Citigroup dropped their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $13.33 on Monday. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.67 and a beta of 1.28. Syndax Pharmaceuticals, Inc. has a one year low of $9.66 and a one year high of $25.07. The company has a 50 day moving average price of $13.08 and a 200 day moving average price of $14.84.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. As a group, equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).